Literature DB >> 2730962

Cell dissociation techniques in human breast cancer--variations in tumor cell viability and DNA ploidy.

B M Ljung1, B Mayall, C Lottich, C Boyer, S S Sylvester, G S Leight, H F Siegler, H S Smith.   

Abstract

Approximately 70% of breast cancers contain cell populations with hyperdiploid (greater than G0/G1) DNA content; however, cells cultured from breast cancers have only diploid DNA contents and karyotypes. Mechanically dissociated cells rarely, if ever, grow in culture, while enzymatically dissociated cells do grow in most cases. To determine if cell dissociation techniques used to prepare cells for culture and other laboratory procedures select for cells with specific features, and if tumor cells are killed in the process, breast cancer cells obtained by mechanical dissociation and by enzymatic dissociation were examined for DNA content and cell viability (measured by dye exclusion). Mechanical dissociation yielded more dead cells and cells with hyperdiploid (greater than G0/G1) DNA than did enzymatic dissociation. Hyperdiploid cells were also found in the dye-excluding population with each dissociation technique, suggesting that the hyperdiploid cells were not always dead. We conclude that, in vivo, tumors contain cellular subpopulations with low viability and hyperdiploid (greater than G0/G1) DNA patterns. The extent to which these subpopulations are present in a sample depends on the dissociation technique employed. That only diploid cells are found in cultures of primary breast cancers may be because enzymatic dissociation, used to prepare cells for culture, yields predominantly diploid cells. These observations also have important implications for interpreting measurements made on dispersed cells, e.g., viability, DNA content, and other cytochemical markers.

Entities:  

Mesh:

Year:  1989        PMID: 2730962     DOI: 10.1007/bf01806527

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  9 in total

1.  Comparison of different methods of determining cell viability after exposure to cytotoxic compounds.

Authors:  B K Bhuyan; B E Loughman; T J Fraser; K J Day
Journal:  Exp Cell Res       Date:  1976-02       Impact factor: 3.905

2.  Aspiration biopsy cytology in diagnosis of thyroid cancer.

Authors:  T Löwhagen; J S Willems; G Lundell; R Sundblad; P O Granberg
Journal:  World J Surg       Date:  1981-01       Impact factor: 3.352

3.  Comparison of dye exclusion assays with a clonogenic assay in the determination of drug-induced cytotoxicity.

Authors:  L M Weisenthal; P L Dill; N B Kurnick; M E Lippman
Journal:  Cancer Res       Date:  1983-01       Impact factor: 12.701

Review 4.  Practical breast carcinoma cell kinetics: review and update.

Authors:  J S Meyer; R W McDivitt; K R Stone; M U Prey; W C Bauer
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872

5.  Growth of diploid cells from breast cancers.

Authors:  S R Wolman; H S Smith; M Stampfer; A J Hackett
Journal:  Cancer Genet Cytogenet       Date:  1985-03-01

6.  Comparative flow DNA analysis of different cell suspensions in breast carcinoma.

Authors:  A Chassevent; A Daver; G Bertrand; H Coic; J Geslin; M C Bidabe; P George; F Larra
Journal:  Cytometry       Date:  1984-05

7.  Invasiveness and ploidy of human mammary carcinomas in short-term culture.

Authors:  H S Smith; L A Liotta; M C Hancock; S R Wolman; A J Hackett
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

8.  Convention on nomenclature for DNA cytometry. Committee on Nomenclature, Society for Analytical Cytology.

Authors:  W Hiddemann; J Schumann; M Andreef; B Barlogie; C J Herman; R C Leif; B H Mayall; R F Murphy; A A Sandberg
Journal:  Cancer Genet Cytogenet       Date:  1984-10

Review 9.  The biology of breast cancer at the cellular level.

Authors:  H S Smith; S R Wolman; A J Hackett
Journal:  Biochim Biophys Acta       Date:  1984
  9 in total
  19 in total

1.  TGF-β receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms.

Authors:  Sergey V Novitskiy; Michael W Pickup; Agnieszka E Gorska; Philip Owens; Anna Chytil; Mary Aakre; Huiyun Wu; Yu Shyr; Harold L Moses
Journal:  Cancer Discov       Date:  2011-10       Impact factor: 39.397

2.  TGF-β signaling in myeloid cells is required for tumor metastasis.

Authors:  Yanli Pang; Sudheer Kumar Gara; Bhagelu R Achyut; Zhaoyang Li; Hannah H Yan; Chi-Ping Day; Jonathan M Weiss; Giorgio Trinchieri; John C Morris; Li Yang
Journal:  Cancer Discov       Date:  2013-05-09       Impact factor: 39.397

3.  CCL9 Induced by TGFβ Signaling in Myeloid Cells Enhances Tumor Cell Survival in the Premetastatic Organ.

Authors:  Hangyi H Yan; Jian Jiang; Yanli Pang; B R Achyut; Michael Lizardo; Xinhua Liang; Kent Hunter; Chand Khanna; Christine Hollander; Li Yang
Journal:  Cancer Res       Date:  2015-10-19       Impact factor: 12.701

4.  Deletion of TGF-β signaling in myeloid cells enhances their anti-tumorigenic properties.

Authors:  Sergey V Novitskiy; Michael W Pickup; Anna Chytil; Dina Polosukhina; Philip Owens; Harold L Moses
Journal:  J Leukoc Biol       Date:  2012-06-08       Impact factor: 4.962

5.  Gr-1+CD11b+ cells are responsible for tumor promoting effect of TGF-β in breast cancer progression.

Authors:  Zhaoyang Li; Yanli Pang; Sudheer Kumar Gara; B R Achyut; Christopher Heger; Paul K Goldsmith; Scott Lonning; Li Yang
Journal:  Int J Cancer       Date:  2012-05-08       Impact factor: 7.396

6.  Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung.

Authors:  Hannah H Yan; Michael Pickup; Yanli Pang; Agnieszka E Gorska; Zhaoyang Li; Anna Chytil; Yipeng Geng; Jerome W Gray; Harold L Moses; Li Yang
Journal:  Cancer Res       Date:  2010-07-14       Impact factor: 12.701

7.  Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis.

Authors:  Li Yang; Jianhua Huang; Xiubao Ren; Agnieszka E Gorska; Anna Chytil; Mary Aakre; David P Carbone; Lynn M Matrisian; Ann Richmond; P Charles Lin; Harold L Moses
Journal:  Cancer Cell       Date:  2008-01       Impact factor: 31.743

Review 8.  Technologies for deriving primary tumor cells for use in personalized cancer therapy.

Authors:  Abhisek Mitra; Lopa Mishra; Shulin Li
Journal:  Trends Biotechnol       Date:  2013-04-16       Impact factor: 19.536

9.  Intravenous administration of Gr-1+CD11b+ myeloid cells increases neovascularization and improves cardiac function after heart infarction.

Authors:  Jianhua Huang; Gang Lv; Yongfen Min; Li Yang; P Charles Lin
Journal:  Int J Cardiol       Date:  2013-04-16       Impact factor: 4.164

10.  Contribution of in vitro comparison of colorectal carcinoma cells from primary and metastatic lesions to elucidation of mechanisms of tumor progression and response to anticancer therapy.

Authors:  Lukáš Krbal; Veronika Hanušová; Jiří Soukup; Stanislav John; Petra Matoušková; Aleš Ryška
Journal:  Tumour Biol       Date:  2016-01-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.